Benzinga | Oct 14, 2020 07:58AM EDT

Guggenheim Upgrades AnaptysBio to Buy, Announces $36 Price Target

Guggenheim analyst Yatin Suneja upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy and announces $36 price target.